Moreover, in mouse models, genetic ablation of DPP4 resulted in improved insulin sensitivity and liver function, while gemigliptin alleviated both liver fibrosis and mitochondrial dysfunction [203–205]. The gene discussed is INS; the disease is Hepatic fibrosis.